Excellent summary and infographic of CagriSema phase 3 data as presented on ADA Scientific Sessions in New Orleans Many thanks to Ahmad Bahareth, MD for sharing ADA 2026 Update: CagriSema Continues to Impress in Type 2 Diabetes Management By Novo Nordisk Novo Nordisk presented comprehensive Phase 3 data from the REIMAGINE 13 trials, demonstrating that CagriSema (cagrilintide + semaglutide) achieved significant improvements in both glycemic control and body weight across multiple stages of type 2 diabetes
Limitations Several limitations of this study should be acknowledged
If state Medicaid programs estimate the costs from expanded use will outweigh the savings, initial state Medicaid participation may be limited, especially given recent state budget challenges and federal funding cuts
Its worth noting that does laser lipo work better than other methods really depends on your individual body type, concerns, and goals
estimated visceral adipose tissue change: bimagrumab 30 mg/kg, 45.1%
Sustaining sexual function in later life is not merely a matter of physical health